Mahsa Miryan

Dr. Mahsa Miryan

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

7 December 2022 in Food Science & Nutrition
Verified
Journal Article
Open access
MNMostafa Nachvak
Mostafa Nachvak
DSDavood Soleimani
Davood Soleimani
MRMehali Rahimi
Mehali Rahimi
AAAli Azizi
Ali Azizi
MMMehdi Moradinazar
Mehdi Moradinazar
MMMahsa Miryan
Mahsa Miryan
Ginger and its derivatives have been shown to be effective in the prevention and treatment of cancer. We undertook a systematic review to answer the question of whether ginger has a role in modifying the biomarkers of cancer in cell culture conditions and on colorectal cancer in randomized clinical trials. We performed a comprehensive search of the literature from Scopus, Embase, Web of Science, PubMed, Cochrane central register of controlled trials, and Cochrane database of systematic reviews. At first, all 12 papers studied the effect of ginger or its derivatives on cell culture conditions. The results of cell culture studies show that ginger has a powerful role in inducing apoptosis. In the second part, five studies of clinical trials were analyzed. By analyzing antitumor markers of clinical trials, ginger increased some anticancer markers but performed poorly in inducing some anticancer markers. This systematic review showed that the consumption of ginger extract has the potential to prevent and treat colorectal cancer but this ability is weak.

29 September 2020 in Phytotherapy Research
Verified
Journal Article
Closed access
PDF file
DSDavood Soleimani
Davood Soleimani
MMMahsa Miryan
Mahsa Miryan
HTHelda Tutunchi
Helda Tutunchi
JNJamshid Gholizadeh Navashenaq
Jamshid Gholizadeh Navashenaq
ESEhsan Sadeghi
Ehsan Sadeghi
AOAlireza Ostadrahimi
Alireza Ostadrahimi

17 December 2020 in Trials
Verified
Journal Article
Open access
PDF file
MMMahsa Miryan
Mahsa Miryan
MBMohammad Bagherniya
Mohammad Bagherniya
Amirhossein SahebkarAmirhossein Sahebkar
Amirhossein Sahebkar
DSDavood Soleimani
Davood Soleimani
MRMohammad Hossein Rouhani
Mohammad Hossein Rouhani
GAGholamreza Askari
Gholamreza Askari
Objectives: This study aims to investigate the efficacy of curcumin-piperine co-supplementation on disease duration, severity and clinical symptoms, and inflammatory mediators in patients with coronavirus (COVID-19). Trial design: This is a randomized, placebo-controlled, double-blind, parallel arm clinical trial. Participants: All patients aged 20-75 years with the diagnosis of Covid-19 based on the PCR test. The exclusion criteria will include an age less than 20 and more than 75 years, current use of warfarin or other anticoagulant drugs, and the presence of sensitivity to herbal products such as turmeric and pepper. This study will be conducted in academic hospitals affiliated to Isfahan University of Medical Sciences, Isfahan, Iran. Intervention and comparator: Fifty outpatients will be randomly allocated in a ratio of 1:1 to receive a capsule of curcumin-piperine containing 500 mg curcumin plus 5 mg piperine or matching placebo containing 505 mg maltodextrin twice a daily, after lunch and dinner, over a period of 2 weeks. Similarly, 50 inpatients who are admitted to hospital wards excluding intensive care unit (ICU) will be randomly assigned in a ratio of 1:1 to receive a capsule curcumin-piperine or matching placebo (provided by the Sami Labs company) twice a daily, after lunch and dinner, over a period of 2 weeks. Main outcomes: The main outcomes of this study are the efficacy of curcumin-piperine on coronavirus disease’s clinical symptoms, duration, severity, and inflammatory mediators after 2 weeks of curcumin-piperine co-supplementation. Randomisation: Randomization sequences will be generated with the use of a random-number table with a permuted block design (block size of 4) and stratification according to the gender variable (male vs. female). These sequences will be prepared by an independent statistician and will be kept in opaque, sealed, numbered envelopes which will be opened only at the time of enrollment. The allocation ratio in intervention and control groups is 1:1. Researchers and all patients will be unaware of the study-group assignment until the completion of data analyses. Blinding (masking): This study is a double-blind clinical trial (participant, researcher). The curcumin-piperine and placebo supplements are packaged in similar numbered drug containers, and the researcher and all patients will be unaware of the study assignment until the end of the study. Numbers to be randomised (sample size): The calculated total sample size is 100 patients, with 25 patients in each group. Trial Status: The protocol is Version 2.0, May 24, 2020. Recruitment began May 4, 2020, and is anticipated to be completed by April 19, 2021. Trial registration: This trial has been registered by the title of “Effect of curcumin-piperine co-supplementation on disease duration, severity and clinical signs, and inflammatory factors in patients with coronavirus (COVID-19): A randomized, double-blind, placebo-controlled clinical trial study” in the Iranian Registry of Clinical Trials (IRCT) with code “IRCT20121216011763N46”, https://www.irct.ir/trial/47529. The registration date is May 4, 2020. Full protocol: The full protocol is attached as an additional file, accessible from the Trials website (Additional file 1). In the interest in expediting dissemination of this material, the familiar formatting has been eliminated; this Letter serves as a summary of the key elements of the full protocol.

2 November 2018 in Journal of Eating Disorders
Verified
Journal Article
Open access
PDF file
ZAZahra Abbaspoor
Zahra Abbaspoor
NJNahid Javadifar
Nahid Javadifar
MMMahsa Miryan
Mahsa Miryan
PAParvin Abedi
Parvin Abedi
The aim of the present study was to test the validity, reliability and factor structure of the original Mindful Eating Questionnaire (MEQ) for use in an Iranian population. This was a cross-sectional study conducted on 150 women who attended four athletic gyms and met the inclusion criteria in Ahvaz city in July of 2015. After linguistic validation of the Iranian version of the MEQ, the content validity ratio (CVR) and content validity index (CVI) were assessed by an expert panel. Then, exploratory factor analysis (EFA) was performed on the scale constructs and scale reliability (internal consistency and test-retest reliability) was assessed with respect to the psychometric properties of the scale. The CVR and CVI scores for the MEQ were 0.89 and 0.93, respectively. EFA loaded all 28-items with a 5-factor solution (‘awareness’, ‘distraction’, ‘disinhibition’, ‘emotional response’ and ‘external cues’) that jointly accounted for 53.78% of the observed variance. The results of the EFA supported the item ‘When a restaurant portion is too large, I stop eating when I’m full’ being placed in the external cues rather than the disinhibition subscale. This displacement improved the reliability coefficient for this subscale. The results of internal consistency analysis, including Cronbach’s alpha (ranging from 0.73 to 0.81) and intraclass correlation coefficients (ranging from 0.73 to 0.91) were satisfactory. The Persian version of the MEQ appears to be valid and reliable; therefore, it can be an effective tool in designing mindfulness-based interventions for the treatment of individuals with eating disorders, overweight and obesity in an Iranian population.

5 August 2020 in Trials
Verified
Journal Article
Open access
PDF file
MMMahsa Miryan
Mahsa Miryan
PAPezhman Alavinejad
Pezhman Alavinejad
MAMohammadreza Abbaspour
Mohammadreza Abbaspour
DSDavood Soleimani
Davood Soleimani
AOAlireza Ostadrahimi
Alireza Ostadrahimi
Background: Irritable bowel syndrome (IBS) is one of the most frequent and recurrent gastrointestinal diseases. However, up to now, no pharmacological agent has been approved to treat IBS. Emerging evidence showed that inflammation has a vital role in enhancing nervous system sensitivity and perception of abdominal pain in subjects with IBS. Propolis is an herbal substance with a broad spectrum of antioxidants, anti-inflammatory, and prebiotic properties, which might exert beneficial effects to reduce the severity of IBS. The current clinical trial aims to evaluate the efficacy of propolis supplementation on IBS.Methods: This single-center, randomized, double-blind, placebo-controlled clinical trial will be performed to evaluate the effect of propolis supplementation in adult patients with IBS diagnosed with Rome IV criteria. Fifty-two eligible patients will randomly be allocated to receive a propolis tablet (450 mg, containing 100 mg polyphenol compounds) or identical placebo, twice daily for 6 weeks. The primary outcome of the trial is an improvement in IBS severity from baseline to the sixth week of intervention. The secondary outcomes include the change in weight, waist circumference, and IBS quality of life. We will use the paired samplettest or Mann-WhitneyUtest for the within-group comparison and independent samplettest or Wilcoxon rank-sum and chi-square test or Fisher’s exact test for the between-group comparison. Besides, a multivariable-adjusted mean effect will be computed using the ANCOVA test.Discussion: We hypothesize that propolis supplementation would be useful for treating IBS through its antioxidants, anti-inflammatory, and prebiotic properties. This trial will show the results of propolis supplementation, whether positive or negative, on IBS. If the current trial confirms our hypothesis, propolis supplementation can be a new choice in adjunctive therapy of IBS.Trial registration: Iranian Registry of Clinical Trials IRCT20190708044154N1. Registered on 26 December 2019. Updated on 13 February 2020.https://en.irct.ir/trial/40983Sponsor: Tabriz University of Medical Sciences, Tabriz, Iran